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Background: In present study we performed whole transcriptome analysis in plaque psoriasis patients and
compared lesional skin with non-lesional skin and with the skin from healthy controls. We sequenced total RNA
from 12 lesional (LP), 12 non-lesional (NLP) and from 12 normal (C) skin biopsies.
Results: Compared with previous gene expression profiling studies we had three groups under analysis - LP, NLP
and C. Using NLP samples allows to see the transcriptome of visually normal skin from psoriasis patient. In LP skin
S100A12, S100A7A, LCE3E, DEFB4A, IL19 were found up regulated. In addition to already these well-described genes,
we also found several other genes related to psoriasis. Namely, KLK9, OAS2, OAS3, PLA2G, IL36G, IL36RN were found
to be significantly and consistently related to the psoriatic lesions and this finding is supported also by previous
studies. The genes up-regulated in the LP samples were related to the innate immunity, IL17 and IL10 networks. In
NLP samples innate immunity and IL17 network were activated, but activation of IL10 network was not evident. The
transcriptional changes characteristic in the NLP samples can be considered as a molecular signature of “dormant
psoriasis”.
Conclusions: Taken together, our study described the transcriptome profile characteristic for LP and NLP psoriatic
skin. RNA profile of the NLP skin is in between the lesional and healthy skin, with its own specific pattern. We found
that both LP and NLP have up-regulated IL17 network, whereas LP skin has up regulated IL10 related cytokines
(IL19, IL20, IL24). Moreover, IL36G and IL36RN were identified as strong regulators of skin pathology in both LP and
NLP skin samples, with stronger influence in LP samples.
Keywords: Psoriasis, Transcriptome, Gene expression profiling, High-throughput nucleotide sequencing, Functional
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Psoriasis is one of the most prevalent chronic inflamma-
tory disease affecting skin and joints [1]. The disease af-
fects 2–3% of the population worldwide and it can have
variable clinical course and severity [2]. The commonest
form of psoriasis is plaque psoriasis and chronic, sym-
metrical, silvery-scaled plaques characterize this form
[1,3]. Although the cause of psoriasis is unknown, it is
complex disease with multifactorial pathogenesis where
several genes interact and eventually induce active dis-
ease [4-6].* Correspondence: sulev.koks@ut.ee
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unless otherwise stated.Whole-genome analysis of RNA provides useful tool to
study complex disorders and to find common pathways re-
lated to the phenotype. Studies of the psoriatic transcrip-
tome with microarrays and RNA-seq technologies have
revealed very large number of differentially expressed genes
(DEGs) in lesional skin [7-12]. With microarrays more than
1000 genes have been found differentially regulated
between psoriatic and normal control skin [8,10]. These
studies have resulted in the new genes and candidates in-
volved in the pathogenesis of psoriasis. A more recent study
has found that 80% of significantly elevated genes in psoria-
sis lesions are related to the keratinocyte activity and infil-
tration by T-cells and macrophages [9]. In addition to
genechips, recently evolved RNA-seq provides more com-
prehensive overview about the transcriptional landscape.
RNA-seq is able to detect new transcripts and splicing
forms that are undetectable with other tools. There havetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[12,13]. Both of these studies described several new tran-
scripts involved in the psoriasis. In one study three pairs of
lesional and normal skin samples from psoriatic individuals
were analysed [13]. In the most recent study based on biop-
sies of 92 psoriatic patients and 82 normal individuals 3,577
DEGs between lesional and normal skin were described
[12]. In present study, we performed RNA-seq transcrip-
tome analysis of 12 paired lesional (LP) and non-lesional
skin (NLP) samples with 12 samples from healthy controls
(C). Differential gene expression analysis was combined
with functional network annotation. As a result we found
gene expression pattern characteristic for the psoriatic le-
sions and described the molecular signature of the non-
lesional skin of psoriatic patient.
Methods
Patients and controls
The Ethics Review Committee on Human Research of the
University of Tartu approved the protocols and informed
consent forms used in this study. All the participants
signed a written informed consent. The patients and con-
trol subjects in the study were unrelated Caucasians living
in Estonia. Unrelated patients with plaque psoriasis from
the Dermatology Clinic of Tartu University Hospital were
included in the study. Sex- and age-matched (+/− 10
years) control subjects were recruited among patients with
melanocytic nevi at the dermatologic outpatient clinic.
Healthy volunteers were free from inflammatory derma-
toses and without a positive family history of psoriasis.
The main characteristics of the psoriasis patients are pre-
sented in Table 1.
Two 4 mm punch biopsy specimens were taken from








P847 19 M 18 (0.5) 12.5 No N
P652 25 M 13 (12) 18.4 Yes N
P844 27 M 18 (9) 8.8 No N
P848 29 M 26 (3) 3.7 No N
P840 49 M 15 (34) 6.0 No N
P845 52 M 22 (30) 14.0 Yes N
P851 60 M 56 (4) 10.8 No N
P853 28 F 28 (0.5) 23.3 No N
P849 37 F 30 (7) 4.7 No N
P856 54 F 14 (40) 7.3 No Ye
P843 57 F 53 (4) 12.6 No N
P846 58 F 57 (1) 15.2 No N
AoO = Age of Onset, M =male, F = female, PASI = Psoriasis Area and Severity Index,and another from distant non-sun-exposed nonlesional
(NLP sample) skin. One 4 mm punch biopsy specimen
was taken from non-sun-exposed skin of each control sub-
ject (C sample). All biopsy specimens were instantly fro-
zen in liquid nitrogen and stored at -80C° until RNA
extraction.
RNA sequencing
Precellys24 tissue homogenizer (Bertin Technologies,
France) with Cryolys adaptor was used to homogenise
biopsy specimens. Total RNA was extracted with
RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia CA,
USA) according to the manufacturer’s protocol. Isolated
RNA was dissolved in RNase free water and stored in
-80C°. The quality of total RNA was evaluated with
Agilent 2100 Bioanalyzer and the RNA 6000 Nano Kit
(Agilent Technologies Inc., CA, USA). The average RNA
integrity number (RIN) of samples was ≥7.
50 ng of total RNA was amplified by applying Ovation
RNA-Seq System V2 (NuGen, Emeryville, CA, USA)
after which the resulting cDNAs were pooled in equal
amount and the pool was used to prepare the DNA
fragment library with SOLiD System chemistry (Life
Technologies Corp., Carlsbad, CA, USA). Sequencing
was performed using SOLiD 5500W platform and DNA
sequencing chemistry (Life Technologies Corp., Carlsbad,
CA, USA). Raw reads (75 bp) were color-space mapped to
the human genome hg19 reference using Maxmapper al-
gorithm implemented in the Lifescope software (Life
Technologies, Ltd). Mapping to multiple locations was
permitted. The quality threshold was set to 10, giving the
mapping confidence was more than 90. Reads with score
less than 10 were filtered out. Average mapping quality





o Yes No No
o Yes Yes No
o Yes No No
o Yes No No
o Yes Yes Calcipotriol +
betamethasone
o Yes Yes No
o Yes No No
o Yes No No
o No No Topical steroid
s Yes Yes Topical steroid
o No No Topical steroid
o Yes No Topical steroid
PsA = psoriatic arthritis.
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flow. Raw sequencing data with appropriate experimen-
tal information is available in the NCBI Gene
Expression Omnibus (GEO) repository under the acces-
sion number GSE66511 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE66511).
Statistical analysis
Patients and controls were tested for potential bias
caused by covariates.
Non-normalized raw counts were used for the EdgeR
package to perform differential gene expression analysis
after quality control of samples. EdgeR performs model-
based scale normalization, estimates dispersions and ap-
plies negative binomial model. EdgeR is very flexible tool
for RNAseq data analysis to find differentially expressed
genes [14,15]. It implements negative binomial model
fitting followed by testing procedures for determining
differential expression.
As our sample contains paired-samples (lesional and
non-lesional skins are form the same persons) we used
two different approaches. For the paired samples we ap-
plied general linear modelling where the subjects were
added to the contrast matrix. GLM likelihood ratio test
was applied for LP-NLP comparison. Different approach
was applied for comparisons between LP-C and NLP-C.
In this approach we used group-wise comparisons where
negative binomial fitting was followed by exact test. False
discovery rate (FDR) adjustment was used for multiple
testing correction [16]. FDR threshold 0.1 for statistical
significance was applied. Genes with larger differential
expression were defined with logFC threshold 0.5 (i.e. 50%
change between experimental conditions).
Functional annotation of differentially expressed genes
The functional analysis of a gene network was used to
identify the biological functions that are most signifi-
cantly related to the molecules in the network. To define
the functional networks of differentially expressed genes,
data were analyzed by using the Ingenuity Pathway Ana-
lysis (IPA, Ingenuity Systems, www.ingenuity.com) that
calculates a significance score (network score) for each
network. This score indicates whether the likelihood that
the assembly of a set of focus genes in a network could
be explained by random chance alone (e.g., score of 2 in-
dicates that there is a chance of 1 in 100 that the focus
genes are together in a network due to random chance).
A data set containing the gene identifiers and their cor-
responding fold change (log2) values were uploaded into
the IPA software. Each gene identifier was mapped to its
corresponding gene object in the Ingenuity Pathways
Knowledge Base to identify molecules whose expression
was significantly differentially regulated (focus genes or
Networks Eligible molecules). These focus genes wereoverlaid onto a global molecular network developed
from information contained in the Ingenuity Knowledge
Base. Networks of these focus genes were then algorith-
mically generated based on their connectivity. A network
represents the molecular relationships between genes or
gene products, which are represented as nodes, and the
biological relationship between two nodes is represented
as an edge (line). All edges are supported by at least one
reference from the literature, or from canonical informa-
tion stored in the Ingenuity Pathways Knowledge Base.
Fold change difference threshold for the functional ana-
lysis was set on 2 (log2 transformed).
Quantitative real-time PCR
250 ng of total RNA was used with High Capacity RNA-
to-cDNA Kit (Life Technologies Co, USA) for cDNA syn-
thesis. QuantiTect Reverse Transcription Kit (Qiagen) was
applied for cDNA synthesis in case of g1 or s1 assays. Both
cDNA synthesis kits were used according to the manu-
facturer’s protocol. cDNA was used as a template for
TaqMan qRT-PCR in 7900 Fast QRT-PCR System (Life
Technologies Co). Two primers and labelled probe
were used to detect the mRNA expression level of the ref-
erence gene hypoxanthine phosphoribosyl-transferase-1
(HPRT1; primer sequences available upon request). Ex-
pression levels of IL36G, IL36RN, LCE3D, IFI6, TGM1,
SPRR2B, OAS2, CRABP2, S100A12 and PARP9 were
detected with TaqMan Gene Expression Assays (Life
Technologies Co) Hs00219742_m1, Hs01104220_g1, Hs0
0754375_s1, Hs00242571_m1, Hs01070310_m1, Hs015
95682_s1, Hs00942643_m1, Hs00275636_m1, Hs009428
35_g1 and Hs00967084_m1, respectively.
The relative gene expression levels from qRT-PCR
were calculated relative to the reference gene HPRT-1
using 2-ΔCT method. The normality of the data was
tested with Shapiro test and based on its results un-
paired t-test or Mann–Whitney test was used. We also
performed correlation analysis to find the strength of ex-
pressional co-regulation of selected genes.
Results
The effect of covariates
Present study compared skin RNA expressional profiles
in psoriasis patients with healthy controls (C). In
addition, we compared the lesional (LP) and non-
lesional (NLP) skin biopsies from psoriasis patients in
order to find activity related genes. In order to exclude
most common confounding variables, we tested for the
differences in age, body weight, height, BMI and smok-
ing status. There was no statistical difference between
any of the studied covariate. In case of age (38 versus
41) the p-value was 0.61, for height (173 versus 174 cm)
p-value was 0.77, for body weight (79 kg versus 87 kg)
p-value was 0.28, for BMI (26.2 versus 29.0) p-value was
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study groups (p-value 0.4).
RNA sequencing results
RNA sequencing experiment gave high quality reads
with good similarity between different samples (Figure 1a).
Multidimensional scaling analysis indicated good separation
of study groups based on the gene expression fold-change
difference (Figure 1a). In Figure 1a the clear separation of
LP and C samples is evident, whereas NLP samples are be-
tween LP and C. This is expected, as in the LP skin active
inflammation is evident. NLP is a skin without inflamma-
tion, but nevertheless, non-lesional skin of psoriasis patients
has molecular differences compared to the normal skin. In-
deed, differential expression analysis found significant dif-
ferences between all study groups.
We had three different groups in our model: lesional
psoriatic skin (LP, n = 12) paired with the non-lesional
psoriatic skin (NLP, n = 12) and normal skin from healthy










Figure 1 General illustration of study groups. a. Multidimensional scaling plot
controls (C), non-lesional psoriatic skin (NLP) and lesional psoriatic skin (LP). Thi
b. Venn diagram for different comparisons between study groups.(GLM) for paired sample analysis. Comparison between
other groups was done with the exact test (NLP versus C
and LP versus C).
In the lesional psoriatic skin compared to the skin of
healthy controls (LP-C), 7,932 genes were differentially
expressed with the confidence level of FDR < 0.1 (for 30
genes Table 2, for all genes Additional file 1: Table S1).
Applying of LogFC threshold verified that 5,853 genes
are at least 50% different between LP-C (FDR < 0.1).
7,539 genes were differentially expressed (False Discovery
Rate, FDR < 0.1) after pair-wise comparison of lesional
psoriatic skin to the non-lesional skin of psoriasis patients
(LP-NLP) (Additional file 2: Table S2). After logFC
filtering 4,626 genes remained differentially expressed at
least by 50% between LP-NLP. Comparison between non-
lesional psoriatic skin and the skin of healthy controls
(NLP-C) identified 2,595 genes to be differentially
expressed with FDR < 0.1 (Additional file 3: Table S3).
Additional logFC threshold indicated that 970 genes were








of the original data indicates clear separation of experimental groups –
s plot verifies good sampling and confirms reliability of collected data.
Table 2 Differentially expressed genes in psoriatic lesions compared to healthy controls (LP-C)
Symbol logFC logCPM PValue FDR Entrez Gene Name
OAS2 4.43 7.16 9.26E-70 2.14E-65 2'-5'-oligoadenylate synthetase 2
PLA2G4E 2.55 7.60 2.74E-68 3.16E-64 Phospholipase A2, group IVE
KLK9 5.20 4.01 2.20E-67 1.69E-63 Kallikrein-related peptidase 9
S100A12 9.00 4.41 1.25E-65 7.20E-62 S100 calcium binding protein A12
LCE3E 6.99 4.45 6.02E-65 2.78E-61 Late cornified envelope 3E
TGM1 3.42 6.51 4.94E-61 1.90E-57 Transglutaminase 1
OAS3 2.99 7.25 1.01E-59 3.33E-56 2'-5'-oligoadenylate synthetase 3
PARP9 2.20 7.11 2.80E-59 8.08E-56 Poly (ADP-ribose) polymerase, 9
CRABP2 2.49 5.65 1.99E-57 5.10E-54 Cellular retinoic acid binding protein 2
PLA2G4D 4.33 6.10 3.03E-56 7.01E-53 Phospholipase A2, group IVD
IL1F9 5.64 6.61 2.26E-55 4.74E-52 Interleukin 36, gamma
ALOX12B 3.01 7.30 7.12E-55 1.37E-51 Arachidonate 12-lipoxygenase
SAMD9 3.01 6.23 8.59E-55 1.53E-51 Sterile alpha motif domain
IL1F5 3.59 7.91 1.14E-53 1.87E-50 Interleukin 36 receptor antagonist
C10orf99 6.22 5.44 3.20E-52 4.93E-49 Chrom 10 open reading frame 99
DEFB4A 10.43 6.59 6.30E-52 9.09E-49 Defensin. beta 4A
AKR1B10 6.22 4.39 4.02E-51 5.46E-48 Aldo-keto reductase family 1
PAPL 4.01 4.60 1.56E-50 2.01E-47 Iron/zinc purple acid protein
GLTP 2.01 7.42 5.00E-50 6.08E-47 Glycolipid transfer protein
KDM6B −1.36 11.51 1.48E-49 1.71E-46 Lysine (K)-specific demethylase 6B
KYNU 4.49 4.72 2.54E-48 2.79E-45 Kynureninase
RRM2 2.68 5.47 3.29E-48 3.46E-45 Ribonucleotide reductase M2
ZC3H12A 3.06 4.88 2.30E-47 2.31E-44 Zinc finger CCCH-type cont 12A
SDR9C7 2.70 5.00 6.01E-47 5.79E-44 Short chain dehydrogenase/reductase
HPSE 3.47 4.17 1.31E-46 1.21E-43 Heparanase
APOL6 2.23 6.52 1.91E-46 1.69E-43 Apolipoprotein L, 6
NIPAL4 1.39 9.13 6.90E-46 5.90E-43 NIPA-like domain containing 4
DMD −1.81 7.46 9.69E-46 7.99E-43 Dystrophin
S100A7A 10.02 10.30 2.84E-45 2.26E-42 S100 calcium binding protein A7A
LogFC is fold changes differences in log2 scale and it describes how many times gene expression differs between groups. Positive values indicate up-regulation in
psoriasis. LogCPM (log2 counts-per-million) is average gene expression signal in all samples. FDR is genome-wide corrected P-value.
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groups is illustrated in the Venn diagram (Figure 1b).
To illustrate the observed differences and their relations
to the skin conditions, we performed cluster analysis of
the entire sample. Heatmap (Additional file 4: Figure S2)
of top 200 differing genes between LP and C samples with
the lowest FDR values were generated. Moreover, we gen-
erated heatmaps from smaller sample subset based on
their gene expression fold-changes (Figure 2, Additional
file 5: Figure S1). Again, our samples were distinguishable
based on the gene expression data what confirms the qual-
ity of RNAseq data. An interesting pattern was found in
Figure 2. This is comparison of NLP-C and therefore
should illustrate the genes that are different in non-
lesional and control sample. NLP sample has genes thathave similar expressional pattern to the lesional sample
(central block of genes in Figure 2) and about the same
amount of genes that have similar expressional pattern
to the control sample (two blocks in the upper and
lower part of Figure 2). The genes with expressional pat-
tern similar to the lesional sample, represent the genes
that form the molecular signature of psoriasis in non-
lesional skin. These genes can be described as “dormant
pathology” or “background inflammation”, indicating
certain standby situation in non-lesional skin. Interest-
ingly, among these genes are IL1F6 and IL6. IL6 is well
known to be involved in the pathogenesis of psoriasis
[17,18]. IL1F6 (IL36A) is a gene that was recently found






















































































































































































Figure 2 Heatmap of the 50 genes with largest fold change differences between NLP and C samples. Violet bar is for control samples, red bar is
for non-lesional samples and green bar is for lesional skin samples.
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Ingenuity pathway analysis software was used for
functional analysis. We analysed the genes differen-
tially expressed between all three groups and per-
formed three separate analyses. This enabled us to
describe the functional networks that characterize
non-lesional skin and lesional skin. Comparison be-
tween lesional skin (LP) and healthy controls (C) re-
vealed activation of the “Granulocyte adhesion and
diapedesis” (Table 3) as the top enriched canonical
pathway (p = 2.81E-20). In addition, “Agranylocyte ad-
hesion and diapedesis” (p = 6.08E-13) and “Role of IL-
17A in Psoriasis” (p = 8.52E-11) were two other highly
enriched canonical pathways in LP compared to C
sample. In addition to the IL-17 signalling, canonical
pathway “IL-10 signalling” was also significantly
enriched in the lesional samples compared to control
samples. Activation of IL-10 signalling means that
IL19, IL20, IL24 and IL26 were significantly up regu-
lated, whereas IL-10 was not. Activation of IL10 ca-
nonical signalling was not found in NLP samples.Comparison between LP and NLP samples (LP-NLP) in-
dicated the enrichment of the “Granulocyte adhesion and
diapedesis” as the top canonical pathway (p = 1.13E-13,
Additional file 6: Table S4), similarly to the LP-C analysis.
LP samples also exhibited significant activation of the ca-
nonical pathway “Role of cytokines in mediating communi-
cation between immune cells” (p = 2.04E-11). Comparison
between NLP and C samples found up-regulation of
canonical pathway “Role of IL-17A in Psoriasis” (p =
2.31E-08) (Additional file 7: Table S5). However, the
enrichment was not that large as in case of lesional
skin and the number of differentially expressed genes
was reduced on NLP-C comparison (Additional file 3:
Table S3). Therefore, differences were more quantita-
tive than qualitative (Additional file 8: Figure S4 and
Additional file 9: Figure S3. However, there were
some gene sets forming quite distinctive pattern or
footprint characteristic only for the LP sample (Additional
file 9: Figure S3). For instance, the genes LCE3E, SPRR2B,
DEFB4A, S100A7A, S100A8, SERPINB4 and S100A12
were specific only for the lesional and not found in non-
Figure 3 Quantitative real-time PCR analysis confirmed transcriptional differences found with RNA-seq. In case of TGM1, LCE3D and SPRR2B there
is no difference between C and NLP. *** - p < 0.001. ** - p < 0.01.
Table 3 Activated canonical pathways in LP-C comparisons
Ingenuity canonical pathways -log
(p-value)
Ratio
Granulocyte Adhesion and Diapedesis 19.60 0.31
Agranulocyte Adhesion and Diapedesis 12.20 0.25
Role of IL-17A in Psoriasis 10.10 0.79
Atherosclerosis Signaling 9.75 0.25
Pathogenesis of Multiple Sclerosis 9.73 0.90
Differential Regulation of Cytokine Production in
Intestinal Epithelial Cells by IL-17A and IL-17F
9.54 0.61
Differential Regulation of Cytokine Production in
Macrophages and T Helper Cells by IL-17A and IL-17F
8.91 0.67
Role of Hypercytokinemia/hyperchemokinemia
in the Pathogenesis of Influenza
8.38 0.39
LXR/RXR Activation 6.29 0.20
Role of Pattern Recognition Receptors in Recognition
of Bacteria and Viruses
6.13 0.22
Role of Cytokines in Mediating Communication
between Immune Cells
5.89 0.31
Altered T Cell and B Cell Signaling in Rheumatoid
Arthritis
5.85 0.22
T Helper Cell Differentiation 5.66 0.26
Hepatic Fibrosis / Hepatic Stellate Cell Activation 5.03 0.18
Communication between Innate and Adaptive
Immune Cells
4.86 0.19
IL-10 Signaling 3.95 0.21
Differentially expressed genes were used as a “signature” to find what
biological function is changed in the skin of psoriasis patients.
Keermann et al. BMC Genomics  (2015) 16:322 Page 7 of 11lesional sample (Figure 3). Activation of “IL-10 signal-
ling” was also found only in the LP samples. On the
other hand, IL1F6, IL6, GPR151, WIF1 and
TNFRSF10C were activated in both lesional and non-
lesional samples (Figure 3). Therefore, there are genes
characteristic for the lesional skin and there are genes
what are activated also in the skin without psoriatic le-
sion. The functional impact of non-lesional transcrip-
tional signature needs further studies.Confirmative quantitative real-time PCR
In order to verify the RNA seq findings we performed
quantitative real-time PCR analysis for 10 genes. We
analysed the expression of IL1F5 (IL36RN) and IL1F9
(IL36G) genes and found that their expression profile
correlated very well with the inflammation in the skin.
The results from qRT-PCR were similar with RNA-seq
data and the differences in gene expression levels
followed completely the skin status – C, NLP or LP.
Only in case of TGM1, LCE3D and SPRR2B genes there
wasn’t statistically significant difference between NLP
and C, but still the difference between LP-C and LP-
NLP was significant (Figures 3). These results support
that LCE3D and SPRR2B are genes more characteristic
for the psoriatic lesion, than for the non-lesional skin.
Correlation analysis indicated very high and significant
correlation between the analysed genes (Additional file
10: Figure S6).
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In present study we performed whole transcriptome ana-
lysis of lesional and non-lesional psoriasis skin samples
and compared them with the healthy control samples.
There are several previous studies where transcriptome
changes in psoriasis patients have been analysed
[8-11,21-27]. In most of these studies hybridization
based genechips were used. However, recently several
additional papers reported the results of RNA-seq based
transcriptome analysis [9,12,13,28,29]. One of these
studies was focused on the differences in the small
RNAs [28]. The other studies analysed whole genome
transcriptome [9,12,13,29]. One major difference be-
tween RNA-seq and genechip based transcriptome stud-
ies is the substantially larger number of differentially
expressed genes and the appearance of the genes previ-
ously not discovered in similar studies. This difference
can be explained by the lower detection limit and wider
dynamic range that is characteristic for RNA-seq. How-
ever, the majority of changes described in the genechip
based studies and in published RNA-seq studies are
quite similar. Most of the findings described in our
paper coincide with previously published large scale
RNA-seq study [12]. However, we applied slightly differ-
ent approach and we also found some interesting targets
not described in previous studies. We used total RNA
(not only polyA RNA), we applied only gene-level ana-
lysis and functional annotation of the networks related
to the differential transcriptome signatures. Also, the
statistical approaches in previous studies have been
slightly different. However, despite these technical differ-
ences, the results of our study and previous studies are
generally similar.
Our study revealed significant and substantial differ-
ences between all three groups in their transcriptome
profile. Most remarkably, oligoadenylate synthetases
(OAS2 and OAS3) and phospholipases from A2
(PLA2G4E and PLA2G4D) group were found up regu-
lated in lesional psoriatic skin. OAS2 and OAS3 are re-
lated to the innate immunity and antiviral response
[30]. Recent studies have shown the association of OAS
genes with psoriasis and systemic lupus erythematosus
[31,32]. OAS genes have thoroughly been discussed as
part of the IFN signature in several studies focusing on
psoriasis [24,33]. Phospholipases A2 are enzymes re-
lated to the metabolism of fatty acids in membrane
phospholipids and related to the inflammatory signal-
ling pathways [34]. Lipid metabolism and antimicrobial
defence pathways are shown activated during psoriasis
[10]. Moreover, OAS and PLA genes have also been
found in other psoriasis transcriptome studies [12,29].
Therefore, these genes are clearly linked with the psor-
iasis and their general role in the chronic inflammatory
conditions is shown in previous papers.Another interesting set of genes we found activated
during psoriasis are interleukin-36 (IL36) cytokines that
belong to interleukin-1 family (IL1F). Namely, with very
high confidence (FDR below 1E-50) we found IL1F9
(IL36G) and IL1F5 (IL36RN) up regulated in lesional
skin samples. Quantitative real-time PCR verified our
findings and even confirmed IL36G and IL36RN expres-
sion to be significantly associated with the skin condi-
tion. Expression was statistically different even between
C and NLP skin samples, in LP samples the expression
was even more elevated. IL36G is a recently discovered
novel member of IL-1 family of cytokines [35]. IL36G
has been shown to be involved in innate immunity and
all IL36 cytokines (except IL36RN) have proinflamma-
tory activity [36-38]. We can consider the activation of
IL36G as the most significant finding and propose the
family of these genes to be important biomarkers for
psoriasis. Indeed, one recent study identified IL36G as
the most outstanding biomarker for psoriasis [39]. Sev-
eral other studies confirm the involvement of IL36 cyto-
kines in the psoriasis [19,36,40]. More precisely, IL36G
was recently identified as one of the 13 hallmark psoria-
sis genes universally or near-universally up-regulated in
psoriasis lesions [40]. IL-1 family members play a key
role in the function of innate and adaptive immunity
and are new promising targets for immunpathologies
[41]. In our study we only found IL36 cytokines (IL36G,
IL36RN and IL36A) to be related to psoriasis. IL37
(IL1F7) was up-regulated only in the non-lesional psori-
atic skin, which makes its role in psoriasis very intri-
guing. In another previous study using RNA-seq for
psoriasis samples the IL37 was found to be down-
regulated in lesional skin [12]. Therefore, our results
confirm previous studies, that IL36 genes have signifi-
cant role in regulation of psoriasis and psoriasis activity.
Pathway analysis found clear activation of innate
immune response and inflammation. Pathway “Role of
IL-17A in Psoriasis” was enriched in both LP-C and
NLP-C comparisons (Table 3 and Table 4). The finding
that the IL-17 pathway is activated during psoriasis is
not new and suits with findings from previous studies
[42]. Moreover, the IL36 cytokine discussed in previous
section is also linked to the IL-17 network. Granulocyte
and agranulocyte adhesion canonical pathways illustrate
the activation of inflammatory pathways and inflamma-
tory conditions. Additional file 8: Figure S4 illustrates
gene expression profiles compared between LP and C
samples. It is visible that the majority of genes are up-
regulated and they are involved in inflammation. Com-
parison of Additional file 8: Figures S4, Additional file 9:
Figure S3 and Additional file 11: Figure S5 illustrates how
the number of activated genes is decreasing as inflamma-
tory conditions getting milder (from lesional to non-
lesional and healthy skin). Additional file 9: Figure S3 has
Table 4 Activated canonical pathways in NLP-C comparisons
Ingenuity canonical pathways -log
(p-value)
Ratio
Role of IL-17A in Psoriasis 7.64 0.50
γ-linolenate Biosynthesis II (Animals) 4.05 0.21
Granulocyte Adhesion and Diapedesis 3.80 0.08
Role of Hypercytokinemia/hyperchemokinemia
in the Pathogenesis of Influenza
3.62 0.15
Atherosclerosis Signaling 3.10 0.08
Altered T Cell and B Cell Signaling in
Rheumatoid Arthritis
3.09 0.09
Agranulocyte Adhesion and Diapedesis 3.02 0.07
Role of Cytokines in Mediating Communication
between Immune Cells
3.02 0.13
Differential Regulation of Cytokine Production in
Macrophages and T Helper Cells by IL-17A and IL-17F
2.82 0.22
LPS/IL-1 Mediated Inhibition of RXR Function 2.72 0.06
Stearate Biosynthesis I (Animals) 2.51 0.10
Primary Immunodeficiency Signaling 2.44 0.09
Differential Regulation of Cytokine Production in
Intestinal Epithelial Cells by IL-17A and IL-17F
2.41 0.17
IL-17 Signaling 2.34 0.09
Communication between Innate and Adaptive
Immune Cells
2.33 0.07
Uracil Degradation II (Reductive) 2.32 0.18
Differentially expressed genes were used as a “signature” to find what
biological function is changed in the skin of psoriasis patients.
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etic network. On the other hand, the Additional file 10:
Figure S6 illustrates genes that are related to the back-
ground inflammation in the non-lesional psoriatic skin.
Most well known psoriasis related genes activated in
non-lesional skin are IL6, IL22, IL36A, IL36G, IL19,
IL20, S100A7 and S100A12. One previous study has
also described similar “pre-psoriatic” gene expression
signature [10]. In accordance with this study, we found
that the gene expression differences between LP and C
samples were more prominent than differences between
NLP and C samples. We can conclude that non-
lesional skin in psoriasis patients, while considered nor-
mal, still contains molecular signature characteristic for
psoriasis.
Difference between NLP and C samples may be caused
by the confounding covariates that should be considered.
After analysis of the distribution of covariates in study
groups we found no statistical difference in age (p = 0.61),
body weight (p = 0.30), height (p = 0.77), BMI (p = 0.32)
and smoking status (p = 0.41) between controls and pa-
tients. Based on these data we can assume, that the influ-
ence of covariates is minimal and the transcriptional
differences are caused by the psoriasis.Taken together, the most of the genes we found have
also been identified in earlier studies. Here we described
results of complex analysis of the transcriptional signa-
tures characteristic for lesional and non-lesional psori-
atic skin and normal skin. There are several published
results on the transcriptional changes of the psoriasis
and in large extend the results are coinciding. However,
differences exist in technical details (total RNA versus
polyA RNA), statistical models and study designs
(lesional versus non-lesional or lesional-non-lesional-
normal). Our study design allowed us to use wider
model (comparison between three conditions) and to
gain more detailed information about the psoriasis. We
found significant activation of IL36 cytokines, what has
not been described in previous studies. Moreover, we
found that IL17 related cytokines are also activated in
non-lesional psoriatic biopsies indicating more general
immune pathology in the skin. Therefore, even the skin
looks noormal, immune system inside the skin is still
altered.
Conclusions
We found the genes of IL36 cytokine family to be in-
volved in the pathogenesis of psoriasis. These genes have
received very little attention in previous research and
therefore, further exploration of their regulation can give
new insights to the psoriasis.
Availability of supporting data
The data set supporting the results of this article is avail-
able in the NCBI Gene Expression Omnibus (NCBI-




Additional file 1: Table S1. The list of 500 most significant differentially
expressed genes based on comparison of LP to the C. LogFC is fold
changes differences in log2 scale and it describes how many times gene
expression differs between groups. Positive values indicate up-regulation
in psoriasis. LogCPM (log2 counts-per-million) is average gene expression
signal in all samples. FDR is genome-wide corrected P-value.
Additional file 2: Table S2. The list of 500 most significant differentially
expressed genes based on comparison of LP to the NLP skin. LogFC is
fold changes differences in log2 scale and it describes how many times
gene expression differs between groups. Positive values indicate up-regulation
in psoriasis. LogCPM (log2 counts-per-million) is average gene expression
signal in all samples. FDR is genome-wide corrected P-value.
Additional file 3: Table S3. The list of 500 most significant differentially
expressed genes based on comparison of NLP skin to the C skin. LogFC
is fold changes differences in log2 scale and it describes how many times
gene expression differs between groups. Positive values indicate up-regulation
in psoriasis. LogCPM (log2 counts-per-million) is average gene expression
signal in all samples. FDR is genome-wide corrected P-value.
Additional file 4: Figure S2. Heatmap of the 50 genes with largest fold
change differences after pairwise comparison of LP and NLP samples.
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Additional file 5: Figure S1. Heatmap of the 50 genes with largest fold
change differences between LP and C samples. Violet bar is for control
samples, red bar is for non-lesional samples and green bar is for lesional
skin samples.
Additional file 6: Table S4. Activated canonical pathways in LP sample
compared to NLP sample.
Additional file 7: Table S5. Activated canonical pathways in NLP-C
comparions.
Additional file 8: Figure S4. Activated gene expression network
related to psoriasis based on the differential gene expression profile
between LP and NLP. The gene expression network was constructed
based on their biological role. The figure illustrates expressional changes
(red genes are higher, green genes are lower expressed) of particular
genes and their cellular location (extracellular, membrane, cytoplasm or
nucleus) in relation with other genes in particular network.
Additional file 9: Figure S3. Activated psoriasis-related gene expression
network based on the differential gene expression profile between LP
and C. The gene expression network was constructed based on their
biological role. The figure illustrates expressional changes (red genes are
higher, green genes are lower expressed) of particular genes and their
cellular location (extracellular, membrane, cytoplasm or nucleus) in
relation with other genes in particular network.
Additional file 10: Figure S6. Correlation analysis of the genes
analysed with quantitative real-time PCR.
Additional file 11: Figure S5. Activated psoriasis gene expression
network based on the differential gene expression profile between NLP
and C. The gene expression network was constructed based on their
biological role. The figure illustrates expressional changes (red genes are
higher, green genes are lower expressed) of particular genes and their
cellular location (extracellular, membrane, cytoplasm or nucleus) in
relation with other genes in particular network.
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